Bulletin
Investor Alert

New York Markets Open in:

GT Biopharma Inc.

NAS: GTBP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 8, 2022, 5:35 p.m.

/zigman2/quotes/200365724/composite

$

2.70

Change

-0.25 -8.47%

Volume

Volume 2,312

Quotes are delayed by 20 min

/zigman2/quotes/200365724/composite

Previous close

$ 2.79

$ 2.95

Change

+0.16 +5.73%

Day low

Day high

$2.80

$3.00

Open

52 week low

52 week high

$1.51

$11.22

Open

Annual Financials for GT Biopharma Inc.

Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue -----
Cost of Goods Sold (COGS) incl. D&A 2,0007,0004,000--
COGS excluding D&A -----
Depreciation & Amortization Expense 2,0007,0004,000--
Depreciation 2,0007,0004,000--
Amortization of Intangibles -----
Gross Income (2,000)(7,000)(4,000)--
20172018201920202021 5-year trend
SG&A Expense 135.57M21.55M11.45M6.76M57.52M
Research & Development 1.07M9.07M1.67M485,0009.59M
Other SG&A 134.5M12.48M9.79M6.28M-
Other Operating Expense ----242,760
Unusual Expense -228.52M4.6M17.98M(182,000)
EBIT after Unusual Expense -(250.07M)(16.06M)(24.75M)(57.58M)
Non Operating Income/Expense --(20.46M)(230,000)-
Non-Operating Interest Income ----38,000
Equity in Affiliates (Pretax) -----
Interest Expense 8.6M9.12M2.13M3.32M718,000
Gross Interest Expense 8.6M9.12M2.13M3.32M718,000
Interest Capitalized -----
Pretax Income (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Minority Interest Expense -----
Net Income (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
Preferred Dividends -----
Net Income Available to Common (144.17M)(259.19M)(38.65M)(28.3M)(58.01M)
EPS (Basic) (146.16)(87.70)(11.42)(6.45)(2.06)
Basic Shares Outstanding 986,4122.96M3.38M4.39M28.16M
EPS (Diluted) (146.16)(87.70)(11.42)(6.45)(2.06)
Diluted Shares Outstanding 986,4122.96M3.38M4.39M28.16M
EBITDA (135.57M)(21.55M)(11.45M)(6.76M)(57.76M)
Link to MarketWatch's Slice.